GS Effex® Cell Line for Enhanced Antibody Effector Function

All you love from GS Xceed®, now fucose-free.

GS Effex®, derived from Lonza’s leading GS Xceed® cell line, produces molecules that are 100% free of fucose and demonstrate increased potency, without compromising on the titers, growth, stability and product quality that GS Xceed® is known for.

Contact us

GS Effex® Cell Line

>35 Years' Experience

We have extensive experience in developing and delivering with market leading protein expression platforms.

Scalable and Regulatory-compliant Processes

We can help you develop robust, efficient, scalable and regulatory-compliant processes to equip you for ultimate commercial success.

>75 Molecules

In clinic manufactured with our expression platforms.

Produce more potent and effective cytotoxic therapeutic antibodies

The interaction of the IgG antibody Fc region with Fc receptors on immune effector cells engages antibody-dependent cellular cytotoxicity (ADCC) to induce target cell death. Removal of fucose residues on the Fc region has been shown to enhance ADCC, increasing the potency of antibody immunotherapies.

GS Effex^®, derived from Lonza’s leading GS Xceed^® cell line, has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose, yet retains all of the desirable performance attributes of GS Xceed^®.

Download the flyer

Fucosylated antibody

Afucosylated antibody

Access to industry-leading technologies

GS Effex^® is available to license as part of Lonza’s GS Gene Expression System^®.A plug and play addition to the GS^®toolbox, it is fully compatible with GS^® workflows and processes.

Related Technologies

GS Xceed® Gene Expression System

Our GS Gene Expression System® is a market-leading CHO based protein expression technology platform. Express a diverse range of biologic drugs.

GS piggyBac® Transposon Technology

We provide unique and versatile transposon based cell line engineering technology that combined with our GS Expression System® results in increased...

GS Discovery® Transient Expression Platform

GS Discovery® comprises a set of optimized transient expression processes to support early stage expression of a range of therapeutic molecules.

XS Technologies® | Pichia & E.coli Expression

Our versatile XS Technologies® offer an extensive microbial expression toolbox, including the XS® Pichia and E.coli Expression Systems.

Expression Technical Support

Technical support for your development journey, based on over 35 years of expertise in protein expression and 20 years with viral gene manufacturing.

Our locations

Our R&D Centers of Excellence

Explore our locations

Cambridge, United Kingdom

Cambridge, United Kingdom

Slough exterior

Slough, United Kingdom

Visp in the Fall

Visp, Switzerland

Explore our locations

Biologics

Related Insights

Visit Knowledge Center

Experts in Expression: Recent Advances in CHO Upstream Bioproduction

Constantly evolving biopharmaceutical pipelines require continuous evolution of CHO-based...

Creating Next-Generation CHO Expression Platforms Through Application of Omics Technologies

Chinese hamster ovary (CHO)-based biomanufacturing platforms have transformed the industrial...

man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough

Webinar (on-demand)

Innovative Solutions for Enhancing Biotherapeutic Expression and Development

The range of molecular formats being explored in drug discovery and development has expanded far...

The Crucial Role of GS-CHO Innovation in Biopharmaceutical Progress

With a long standing track record of success, GS-CHO based expression systems have become the most...

Understanding Glycosylation in Antibodies

Proteins often undergo a variety of post-translational modifications (PTMs) after their initial...

Making More Effective Antibody-Based Immunotherapies with the GS Effex® Cell Line

Antibody-based immunotherapies can mediate cancer cell death via multiple mechanisms, including...

Webinar (on-demand)

Advancing Early-Stage Bispecific Discovery Programs Towards Clinical Success, With GS Discovery® and...

Watch this webinar with Dr. Jin Lu to learn how Lonza’s novel expression tools can advance your...

Presentation (on-demand)

Solutions for High Titre Expression of Cancer Immunotherapies

Biological pipelines for oncology indications are evolving, with next-generation molecules joining...

Visit Knowledge Center

Sign up. Stay up-to-date.